Quantitative Systematic Strategies’s Acadia Pharmaceuticals ACAD Stock Holding History

Quantitative Systematic Strategies’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-15,281	Closed	-$408K	–	453
2019 Q2	$408K	Buy	15,281 +6,134	+67%	+$157K	0.08%	287
2019 Q1	$246K	Buy	+9,147	New	+$214K	0.06%	281
2017 Q2	–	Sell	-6,069	Closed	-$209K	–	432
2017 Q1	$209K	Buy	+6,069	New	+$214K	0.06%	318
2016 Q1	–	Sell	-8,559	Closed	-$307K	–	404
2015 Q4	$307K	Buy	+8,559	New	+$302K	0.08%	411
2015 Q2	–	Sell	-14,843	Closed	-$495K	–	497
2015 Q1	$495K	Buy	+14,843	New	+$510K	0.14%	201

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Quantitative Systematic Strategies's ACAD Position: Q3 2019 in Review

Quantitative Systematic Strategies sold out of Acadia Pharmaceuticals (ACAD) in Q3 2019, closing a stake of 15,281 shares — an estimated $408K sold.

Quantitative Systematic Strategies first reported a position in ACAD in Q1 2015 and held it in 5 quarters. The position peaked at $495K in Q1 2015. 231 funds tracked by Wall St. Rank hold ACAD as of Q3 2019.

Quantitative Systematic Strategies reported no remaining Acadia Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Quantitative Systematic Strategies sold 15,281 Acadia Pharmaceuticals shares in Q3 2019, an estimated $408K.
Quantitative Systematic Strategies first reported a position in Acadia Pharmaceuticals in Q1 2015 and held it in 5 quarters.
Quantitative Systematic Strategies's Acadia Pharmaceuticals position peaked at $495K in Q1 2015.
231 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2019.

Based on Quantitative Systematic Strategies's 13F filing for Q3 2019, filed 7 Nov 2019.